

# Curriculum Vitae – João Conde, PhD

## PERSONAL DETAILS

Name: João Diogo Osório de Castro Conde

Place and birthdate: Lisbon, Portugal; February 5, 1982

Professional Website: <https://www.conde-nanolab.com/>

Contact: [joao.conde@nms.unl.pt](mailto:joao.conde@nms.unl.pt) ; [joaodconde@gmail.com](mailto:joaodconde@gmail.com)

ORCID: [0000-0001-8422-6792](https://orcid.org/0000-0001-8422-6792)

Scopus ID: [56992468300](https://scopus.com/authid/detail.url?authorID=56992468300)

Hobby: Painting



João Conde is a **Group Leader** (*Cancer NanoMedicine Lab*) and **Professor** at **NOVA Medical School, Universidade Nova de Lisboa, ToxOmics**. In 2014, he received his **PhD in Biology**, specialty in NanoBiotechnology from the **Universidade Nova de Lisboa** and the **Universidad de Zaragoza**, under the **FP7 European Consortium NanoScieE<sup>+</sup> – NANOTRUCK**: multifunctional nanoparticles for gene silencing. After, he was a **Marie Curie Fellow** at the **Massachusetts Institute of Technology, Harvard-MIT Division for Health Sciences and Technology** and in **School of Engineering and Materials Science** at **Queen Mary University of London**. From 2017 to 2019, he was a **Junior Investigator** at **Instituto de Medicina Molecular**. In 2019, he won an **ERC Starting Grant (1.5M€)** from the **European Research Council** to build a genetic biobarcode to profile breast cancer heterogeneity. Since the **ERC Starting Grant**, he was able to publish **more than 50 publications** in top journals, filled **3 patents** and mentored **more than 20 students and post-docs**.

He is also **co-founder of the biotech company TargTex**, Targeted Therapeutics for Glioblastoma **Multiforme with a 4M€ funding**. Since 2020, he is also a **collaborator at Global Burden of Disease (GBD) Consortium** from the **Institute for Health Metrics and Evaluation (IHME), University of Washington**. In 2023, he partnered with **Vector Bioscience Cambridge and AstraZeneca to develop RNA-based cancer therapies from the European Innovation Council (2.5M€)**. In 2023, was elected for the **Scientific Advisory Board of FCT: Fundação para a Ciência e a Tecnologia**.

The main aspects related to the recognition and diffusion of his early contributions are: **nearly 100 articles (average impact factor of 25 in the last 5 years) with over 2200 co-authors in top-tier journals** of Cancer Therapy, Oncology, Nanotechnology/Materials Science and NanoMedicine (*The Lancet, Nature Materials, The Lancet Oncology, Nature Nanotechnology, JAMA Oncology, Nature Communications, The Lancet Gastroenterol Hepatol, Nature Rev Methods Primers, PNAS, Accounts of Chemical Research, The Lancet Child Adolesc Health, Progress in Materials Science, ACS Nano, Advanced Materials, JACS, Angewandte Chemie, Advanced Functional Materials, Trends in Cancer, Trends in Biotechnology, Biomaterials, etc.*), **more than 30 articles are as 1st author and more than 50 articles as corresponding author** and cited **more than 8100 times (h-index 46)**. **More than 20** of them have been selected as **Cover** of journals such as *Nature Nanotechnology* (COVID-19 Special Issue), *The Lancet*, *The Lancet Oncology*, *ACS Nano*, *Adv. Functional Materials*, *Trends in Cancer*, *BioTechniques*, etc. In addition, **8 international patents** on nanomaterials-based platforms for cancer therapy and diagnosis were submitted and approved. He was also awarded **several international awards**, including the **2022 World's Top 2% Scientists list by Stanford University**, the **Nanomaterials 2020 Young Investigator Award**, the **2021 Biomaterials Science Emerging Investigator**, the **Top 2% Most cited in Nanoscience/Nanotechnology from PLOS Biology**, the **Wellcome Image Awards 2017**, the **Nano-Micro Letters Researcher Award**, and the **National Cancer Institute Image award**.

## EDUCATION

- **PhD in Biology**, Specialty **Nanobiotechnology**, *Summa cum laude*, **Universidade Nova de Lisboa**, Portugal and Instituto de Nanociencia de Aragón at **Zaragoza University**, Spain, 2013.
- **MSc in Biology**, *Summa cum laude*, **Universidade Lusófona de Humanidades e Tecnologias**, Portugal, 2008.

## APPOINTMENTS

- March 2023 – Present: **Scientific Advisory Board** (Health and Life Sciences) at **FCT: Fundação para a Ciência e a Tecnologia** (Portugal).
- February 2020 – Present: **Group Leader, Principal Investigator** (Cancer NanoMedicine Lab) at **ToxOmics, NOVA Medical School, Universidade Nova de Lisboa** (Portugal).
- February 2020 – Present: **Assistant Professor** at **NOVA Medical School, Universidade Nova de Lisboa** (Portugal).
- September 2019 – Present: Co-founder and Shareholder of **TargTex SA start-up company: Targeted therapies for the treatment of brain cancer** (Portugal).
- October 2017 – January 2020: **Junior Researcher** at **Instituto de Medicina Molecular, Faculdade de Medicina de Lisboa** (Portugal).
- April 2016 – April 2017: **Marie Curie Early-Stage Career Fellow** at School of Engineering and Materials Science at **Queen Mary University London** (UK).
- February 2014 – April 2016: **Marie Curie Early-Stage Career Fellow** at the **Massachusetts Institute of Technology (MIT), Harvard–MIT Division for Health Sciences and Technology, Institute for Medical Engineering and Science** (US).
- January 2010 – December 2013: **Science and Technology Foundation PhD Fellow** (FCT, SFRH/BD/ 62957/2009), **Universidade Nova de Lisboa** (Portugal) and **Zaragoza University** (Spain).
- January 2009 – January 2010: Research fellowship (PTDC/BIO/66514/2006), Research Centre for Human Molecular Genetics, **FCT/UNL, Universidade Nova de Lisboa** (Portugal).
- September 2007 – December 2008: Under-graduate fellowship, Molecular Genetics Department at **NOVA Medical School, Universidade Nova de Lisboa** (Portugal).

## BACKGROUND

- Cancer Nanomedicine, Nanotechnology and Materials Science.
- Oncology and Biomedicine.
- Multifunctional nanomaterials for Cancer therapy and diagnostics.
- Genetic therapies based on DNA/RNA, siRNA/miRNA.
- Gene therapy, drug delivery, tumor targeting.
- Smart clinical platforms based on new materials and technologies for local therapy in cancer.
- Gene therapy/Antisense DNA/RNA Interference/microRNA, gene editing CRISPR/Cas9.
- *In vivo* cancer mice models (breast, colon, gastric, glioblastoma, prostate, pancreatic, ovarian and lung cancer) – tumour induction and administration (systemic and local) of anti-cancer therapies.

## TEACHING

- 2021 – Present: Invited classes from **Master Course in Biomedical Research**, Curricular Unit Translational & Precision Medicine, **NOVA Medical School, Universidade NOVA de Lisboa**.
- 2020 – Present: **Genetics** from **Master Course in Medicine** (Unidade Curricular de Genética do Mestrado Integrado em Medicina), **NOVA Medical School, Universidade NOVA de Lisboa**.

- 2010 – 2013: Invited Lab classes of **Molecular Diagnostics and Bionanotechnology** from **Master Course in Molecular Genetics and Biomedicine, FCT/UNL, Universidade NOVA de Lisboa.**

### **MENTORING EXPERIENCE**

- Alazne Moreno, **PhD student**, University of Barcelona (Feb 2023-to present).
- Leonardo di Filippo, **PhD student**, School Pharmaceutical Sciences/UNESP (Jan 2023-to present).
- Cristina Volpini, **Erasmus student**, University of Pavia (Jan 2023-to present).
- Alessia Privitera, **Erasmus student**, University of Pavia (Jan 2023-to present).
- Marta Santos, **MSc student**, Nova Medical School and FCT-NOVA (Sept 2022-to present).
- Mariana Pereira, **MSc student**, Nova Medical School and Universidade do Algarve (Sept 2022-to present).
- Pedro Ribeiro, **PhD student**, Nova Medical School (Sept 2022-to present).
- Catarina Martins, **PhD student**, Nova Medical School and CIC biomaGUNE (Sept 2022-to present).
- João Pais, **PhD student**, Universidade de Coimbra and Nova Medical School (Sept 2022-to present).
- Ana Cunha, **BSc student**, Nova Medical School (Mar 2022-Jul 2022).
- Carolina Melo, **MSc student**, Faculdade Medicina, Universidade de Coimbra (Mar 2022-Jul 2022).
- Pedro Rosado, **BSc student**, Nova Medical School (Mar 2022-Apr 2022).
- Beatriz Salvado, **BSc student**, Nova Medical School (Feb 2022-Mar 2022).
- Ana Rita Mariano, **BSc student**, Nova Medical School (Feb 2022-Mar 2022).
- Jhenifer Oliveira, **PhD student**, Nova Medical School (Oct 2021-to present).
- Diana Castro Peixoto, **PhD student**, Universidade de Coimbra & Nova Medical School (Sept 2021-to present).
- Joana Amorim, **MSc student**, Nova Medical School (Sept 2021-Oct 2022).
- Diana Sousa, **PhD student**, Nova Medical School (Sept 2020-to present).
- Charlotte Baker, **PhD student**, Instituto de Medicina Molecular (Oct 2017-Oct 2019).
- Daniel Fulop, **MSc student**, Harvard University, Sophomore Internship (Jun 2015-Feb 2016).
- Cristina Violi, **MSc student**, Socrates-Erasmus Programme Italy, (Feb 2013-Aug 2013).
- André Salvada, **BSc student**, Universidade Nova de Lisboa, (Jan 2013-Mar 2013).
- Pedro Dionisio, **BSc student**, Universidade Nova de Lisboa, (Mar 2011-Sept 2011).

### **JOURNAL REVIEWER**

- Nature Reviews Cancer; Nature Materials; Nature Communications; Nature Protocols; PNAS; Accounts Chemical Research; Chemical Reviews; Advanced Drug Delivery Reviews; Progress Polymer Science; Advanced Materials; ACS Nano; Advanced Functional Materials; Nature Asia Materials; Chemical Science; Theranostics; Small; Journal Controlled Release; Nanoscale; Analytical Chemistry; Advanced Healthcare Materials; Scientific Reports; Nanomedicine; Nanotoxicology; Nanomedicine: NBM; Acta Biomaterialia; Journal Materials Chemistry B; PLoS ONE; ACS Applied Materials & Interfaces; Bioconjugate Chemistry; Journal Biomedical Nanotechnology; Sensors & Actuators: B Chemical; Advanced Science; Nanoscale Research Letters; Colloids and Surfaces B: Biointerfaces; Journal of Nanobiotechnology; Biomacromolecules; Drug Development and Industrial Pharmacy; Critical Reviews Oncology/Hematology; International Journal Nanomedicine; Pharmaceutical Medicine; European Polymer Journal; among others.

**Web of Science Review Metrics:** <https://www.webofscience.com/wos/author/record/1246512>

### **RESEARCH EVALUATOR**

- European Research Executive Agency, Brussels.
- The Swiss National Science Foundation, Switzerland.

- Instituto de Medicina Molecular, Faculdade de Medicina de Lisboa, Portugal.
- Kingdom of Saudi Arabia Ministry of National Guard – Health Affairs, Saudi Arabia.

## EDITOR


- **Editorial Board**, *Frontiers in Chemistry* (2022 - to present).
- **Editorial Board**, *Journal of Functional Biomaterials*, MDPI (2021 - to present).
- **Editorial Board**, *Materials*, MDPI (2021 - to present).
- **Editorial Board**, *Exploration*, Wiley (2021 - to present).
- **Editorial Board**, *VIEW*, Wiley (2021 - to present).
- **Review Editor**, *Frontiers Genetics - Toxicogenomics* (2021 - to present).
- **Editorial Board**, *Journal of Nanotheranostics*, MDPI (2020 - to present).
- **Book editor**, “Handbook of Nanomaterials for Cancer Theranostics” by Elsevier (2017 - to present).
- **Volume Editor**, in the *Advanced Nanomaterials Series*, Elsevier (2016 - to present).
- **Editorial Board**, *Nano Biomedicine and Engineering Journal* (2016 - to present).
- **Associate Editor**, *Frontiers in Bioengineering and Biotechnology* (2015 - to present).
- **Associate Editor**, *Frontiers in Molecular Biosciences* (2015 - to present).
- **Associate Editor**, *Frontiers in Materials* (2015 - to present).
- **Guest Associate Editor**, *Frontiers in Chemistry* (2014 - to present).

## MEMBER

- March 2020 – Present: Active collaborator of the **Global Burden Disease (GBD)**, **Institute for Health Metrics and Evaluation (IHME)**, University of Washington (US).

## INTERNATIONAL NETWORKING/COLLABORATORS

- Main collaborators: **Massachusetts Institute of Technology (US)**, **Yale University (US)**, **Harvard Medical School (US)**, **Harvard University (US)**, **Broad Institute of MIT and Harvard (US)**, **Brigham and Women's Hospital (US)**, **Dana-Farber Cancer Institute (US)**, **Duke University (US)**, **University of Pennsylvania (US)**, **Tel Aviv University (Israel)**, **University of British Columbia (Canada)**, **Johns Hopkins University (US)**, **Case Western Reserve University (US)**, **University of Cambridge (UK)**, **University of Oxford (UK)**, **University College London (UK)**, **University of Turin (IT)**, **University Hospital Düsseldorf (Germany)**, **Dublin Institute of Technology (Ireland)**, **Shanghai JiaoTong University (China)**, **University of Glasgow (UK)**, **Fundação Champalimaud (Portugal)**, **iMed.UL (Portugal)**, **Universidade Coimbra (Portugal)**.



## RESEARCH PROJECTS AS PI

- European Research Council - ERC Starting Grant: ERC-StG-2019-848325 – *GelGeneCircuit*: Profiling therapy and heterogeneity in cancer using bioresponsive nanohydrogels for the delivery of logic multicolor genetic circuits (2019-2024). *Funding 1.5M€*

- FCT Grant PTDC/BTM-MAT/4738/2020 – Biomimetic cell membrane-coated vitamin E-based micelles for multimodal pancreatic cancer nanotheranostics (2020-2023). *Funding 250K€*
- FCT Stimulus of Scientific Employment CEECIND/01688/2017 – Hydrogel scaffolds for delivery of gene therapies (2018-2019) National Science Foundation, PT. *Funding 230K€*

### **RESEARCH PROJECTS with INDUSTRY**

- RNA-based cancer therapies. By Vector Bioscience Cambridge and AstraZeneca - European Innovation Council – EIC Transition Grant (2023-2026). *Funding 2.5M€*

### **RESEARCH PROJECTS AS TEAM MEMBER**

- PAIR-Lung: Patient-derived lung cancer organoids for recreating tumor spread through AIR spaces phenomenon. FCT Grant, 2022.07775.PTDC (2022-2024).
- Combined immUNotherapeutiC approach for targeting bone marrow microenvironment in Multiple Myeloma. FCT Grant, PTDC/MED-ONC/1215/2021 (2021-2024).
- Albumedix Ltd. - Recombinant albumin conjugates for cancer therapy (2018).
- SuprHApolymers - Engineering self-assembly of hyaluronan-based glycopolymers with peptides (2016).
- NOF Corporation - Characterization of PEG-based hydrogels (2014-2015).
- NANOTRUCK- Multifunctional gold nanoparticles for gene therapy. EU, ERANET-NanoSciera<sup>+</sup> (2012-2014).
- Silence is golden (siAu) - Silencing the silencers via multifunctional gold nanoconjugates towards cancer therapy. FFCT/FCT/UNL, PTDC/BBB-NAN/1812/2012.
- Nanosystems for delivery of caged compounds. FFCT/FCT/UNL, PTDC/QUI-QUI/ 112597/2009.
- Sensitive and selective detection of DNA/RNA based on functionalized gold nanoparticles - application to pathogen detection, mutation detection and RNA quantification. FFCT/FCT/UNL, PTDC/BIO/66514/2006.

### **START-UP COMPANIES**

- 2019 – Present: Co-founder of *TargTex SA*, Portuguese start-up: Targeted therapies for the treatment of brain cancer. *Portugal Ventures Funding 2M€ + Private Funding, Basi 2M€*

### **PRIZES AND AWARDS**

- 2022 - **World's Top 2% Scientists list**, Stanford University.
- 2021 - **Nanomaterials 2020 Young Investigator Award**, MDPI.
- 2021 – **Top 2% Most Cited Researchers in Nanoscience and Nanotechnologies**, PLOS Biology.
- 2021 - **2021 Biomaterials Science Emerging Investigators**, Royal Society of Chemistry.
- 2019 - **ERC Starting Grant**: ERC-StG-2019-848325, European Research Council, EU.
- 2018 - **Junior Investigator**: FCT Stimulus of Scientific Employment, (CEECIND/01688/2017) National Science Foundation, PT.
- 2017 - **Wellcome Image Awards 2017**: Wellcome Trust, UK.
- 2016 - **Nano-Micro Letters Researcher Award**, Nature Research Society.
- 2016 - **National Cancer Institute Image award**: Cancer close up, US.
- 2013 - **Marie Curie International Outgoing Fellowship** for Career Development, Marie Skłodowska-Curie actions (FP7-PEOPLE-2013-IOF).
- 2009 - **PhD Fellowship** - National Science Foundation - PhD Grant (FCT, SFRH/BD/62957/2009), PT.

## PATENTS

1. Theranostic Nanoprobes for Overcoming Cancer Multidrug Resistance and Methods. **U.S. Application No. 62/118101. MIT Case No. 17685K**, MIT Docket No. 17685.117921.
2. RNA Triple Helix Structures, Compositions, and Methods. **U.S. Application No. 62/216969. MIT Case No. 18323 PCT**, MIT Docket No. 17648-0205.
3. Hydrogel particles, compositions, and methods. **U.S. Application No. 62/339434**.
4. Micro-RNA delivery compositions, devices, and methods. **U.S. Application No. 62/353622**.
5. Functionalized nanoparticles and compositions for cancer treatment and methods. **U.S. Application No. 62/334538**.
6. Hydrogel particle of cystamine cross-linked dextran aldehyde containing imine conjugated doxorubicin and rgd peptide for chemotherapy. **U.S. Application No. PCT/US2017/033542**.
7. TRPV2 Antagonists. **WO EP CN JP AU BR CA EA SG Application No. PCT/PT2018/050035**.
8. TRPV2 Antagonists. **U.S. Application No. US11273152B2**.

## PUBLICATIONS

• More than **90 articles** in high impact journals in fields of Nanomedicine, Oncology and Cancer Therapies and Biomedicine (*The Lancet* **IF202.7**, *Nature Materials* **IF43.8**, *The Lancet Oncology* **IF54.4**, *Nature Nanotechnology* **IF39.2**, *JAMA Oncology* **IF31.8**, *The Lancet Gastroenterology & Hepatology* **IF45.0**, *Nature Communications* **IF14.9**, *The Lancet Child & Adolescent Health* **IF37.7**, *Military Medical Research* **IF34.9**, *PNAS* **IF11.2**, *Accounts of Chemical Research* **IF22.4**, *Progress in Materials Science* **IF39.6**, *Advanced Materials* **IF30.8**, *Materials Today* **IF26.4**, *Nano Today* **IF16.9**, *ACS Nano* **IF15.9**, *JACS* **IF15.4**, *Angewandte Chemie* **IF15.3**, *Advanced Functional Materials* **IF18.8**, *Advanced Science* **IF17.5**, *Advanced Drug Delivery Reviews* **IF13.3**, *ACS Central Science* **IF14.5**, *Trends in Cancer* **IF14.2**, *Trends in Biotechnology* **IF19.5**, *Matter* **IF15.6**, *Biomaterials* **IF12.5**, *The Lancet Child & Adolescent Health* **IF11.3**, *Journal of Controlled Release* **IF7.9**, *Biosensors & Bioelectronics* **IF10.6**, *Nature Asia Materials* **IF10.5**).

• More than **30 articles** as **1<sup>st</sup> author**, and more than **50 articles** as **corresponding author**, all **cited more than 8100 times** (**h-index Google Scholar 46**). Several of them have been selected as **cover page of journals** such as **The Lancet**, **Nature Nanotechnology** (Covid-19 Special Issue), **The Lancet Oncology**, **Trends in Cancer**, **ACS Nano**, **The Lancet Child & Adolescent Health**, **ACS Central Science**, **Adv. Functional Materials**, **JACS**, **Angewandte Chemie**, **ACS Sensors**, **WIREs Nanomedicine & Nanobiotechnology**, **Biomaterials Science**, **ACS Applied Bio Mat**, **Adv. Healthcare Materials**, **Analytical and Bioanalytical Chemistry** and **BioTechniques**.

## PUBLICATIONS (\* corresponding author)

(96 publications, Citations: 8121. h-index *Google Scholar*: 46, h-index *Scopus*: 38)

1. “Bioengineered exosome membrane camouflaged-abiotic nanocarriers: neurodegenerative diseases, tissue engineering and regenerative medicine”. D. Lopes, J. Lopes, M. Pereira-Silva, Diana Peixoto, F. Veiga, S. Yousefiasl, N. Rabiee, **João Conde**, P. Makvandi and A.C. Paiva-Santos. *Military Medical Research* (2023).
2. “Hydrogels for RNA Delivery”. R. Zhong, S. Talebian, Barbara Mendes, G. Wallace, R. Langer, **João Conde\*** and J. Shi\*. *Nature Materials* (2023).
3. “mRNA therapy at the convergence of genetics and nanomedicine”. **João Conde\***, Robert Langer and José Rueff. *Nature Nanotechnology* (2023).

4. “Biopolymeric coatings for local release of therapeutics from biomedical implants”. S. Talebian, Bárbara Mendes, João Conniot, S. Farajikhah, F. Dehghani, Z. Li, D. Bitoque, G. Silva, S. Naficy, **João Conde\*** and G.G. Wallace\*. *Advanced Science* (2023).
5. “Exosome Membrane-Coated Nanosystems: Exploring Biomedical Applications in Cancer Diagnosis and Therapy”. M. Shao, D. Lopes, J. Lopes, S. Yousefias, A. Macário-Soares, Diana Peixoto, I. Ferreira-Faria, F. Veiga, **João Conde**, Y. Huang, X. Chen, A.C. Paiva-Santos and P. Makvandi. *Matter, Cell Press* (2023).
6. “Technological challenges of biomembrane-coated top-down cancer nanotherapy”. João M.J.M. Ravasco, A.C. Paiva-Santos\* and **João Conde\***. *Nature Reviews Bioengineering* (2023).
7. “Using gold nanobeacons as a theranostic technique to recognize, detect, and inhibit specific nucleic acids”. Diana P. Sousa and **João Conde\***. *STAR Protocols, Cell Press* (2022).
8. “Magnetite and bismuth sulfide Janus heterostructures as radiosensitizers for in vivo enhanced radiotherapy in breast cancer”. H. Nosrati, M. Ghaffarlou, M. Salehiabar, N. Mousazadeh, F. Abhari, M. Barsbay, Y.N. Ertas, H. Rashidzadeh, A. Mohammadi, L. Nasehi, H. Rezaeejam, S. Davaran, A. Ramazani\*, **João Conde\*** and H. Danafar\*. *Biomaterials Advances* (2022).
9. “Nucleic acid-based therapy for brain cancer: Challenges and strategies”. Z. Zhang, João Conniot, Joana Amorim, Y. Jin, R. Prasad, X. Yan\*, K. Fan\* and **João Conde\***. *Journal of Controlled Release* (2022) - VSI: Brain Targeting Issue.
10. “Gold nanoconjugates for miRNA modulation in cancer therapy: from miRNA silencing to miRNA mimics”. Diana P. Sousa and **João Conde\***. *ACS Materials Au* (2022) - Rising Stars Issue & Editors’ choice. Featured on COVER
11. “Macrophage cell membrane-cloaked nanoplatfoms in biomedical applications”. J. Lopes, D. Lopes, M. Pereira-Silva, D. Peixoto, F. Veiga, M.R. Hamblin, **João Conde**, C. Corbo, E.N. Zare, M. Ashrafizadeh, F.R. Tay, C. Chen, X. Wang, P. Makvandi and A.C. Santos. *Small Methods* (2022).
12. “The global burden of cancer attributable to risk factors, 2010–2019: a systematic analysis for the Global Burden of Disease Study 2019.” **João Conde & GBD Consortium**. *The Lancet* (2022).
13. “Global, Regional and National Burden of Colorectal Cancer, 1990-2019: A systematic examination for Global Burden of Disease 2019”. **João Conde & GBD Consortium**. *The Lancet Gastroenterology & Hepatology* (2022).
14. “The burden of non-communicable diseases in adolescents in 28 European countries, 1990-2019: A Systematic Analysis of the Global Burden of Diseases, Injuries, and Risk Factors Study.” **João Conde & GBD Consortium**. *The Lancet Child & Adolescent Health* (2022). Featured on COVER
15. “Nano-delivery of nucleic acids”. Bárbara B. Mendes, João Conniot, A. Avital, D. Yao, X. Jiang, X. Zhou, O. Adir, Y. Xiao, N. Sharf-Pauker, H. Liang\*, J. Shi\*, A. Schroeder\* and **João Conde\***. *Nature Reviews Methods Primers* (2022).
16. “Bioinspired Soft Nanovesicles as Site-Selective Imaging and Targeted Therapies of Cancer”. Rajendra Prasad\*, **João Conde\*** to *WIREs Nanomedicine and Nanobiotechnology* (2022).
17. “Prodrug polymeric nanoconjugates encapsulating gold nanoparticles for enhanced X-Ray radiation therapy in breast cancer” H. Nosrati, F. Seidi, A. Hosseinmirzaei, N. Mousazadeh, A. Mohammadi, Mo. Ghaffarlou, H. Danafar, **João Conde\*** and Ali Sharafi\*. *Advanced Healthcare Materials - Rising Star Issue* (2021). Featured on COVER
18. “Controlled delivery of gold nanoparticle-coupled miRNA therapeutics via an injectable self-healing hydrogel”. C.F.T. van der Ven, M.W. Tibbitt, **João Conde**, A. van Mil, J. Hjortnaes, P.A.F.M. Doevendans, J.P.G. Sluijter, E. Aikawa and Robert Langer. *Nanoscale* (2021) - Featured on COVER

19. “The global burden of adolescent and young adult cancer in 2019: An analysis of the Global Burden of Disease Study 2019”. **João Conde & GBD Consortium**. *The Lancet Oncology* (2021). Featured on COVER
20. “Cancer Incidence, Mortality, Years of Life Lost, Years Lived with Disability, and Disability-Adjusted Life Years for 29 Cancer Groups from 2010 to 2019: A Systematic Analysis of Cancer Burden Globally, Nationally, and by Socio-Demographic Index for the Global Burden of Disease Study 2019”. **João Conde & GBD Consortium**. *JAMA Oncology* (2021).
21. “Machine-readable Nanotechnology for future healthcare research”. Andzelika Lorenc, Bárbara B. Mendes, João Coniot, Diana P. Sousa, **João Conde\*** and Tiago Rodrigues\*. *Matter (Cell Press)* (2021).
22. “Global, regional, and national progress toward Sustainable Development Goal 3.2 for neonatal and child health: all-cause and cause-specific mortality findings from the Global Burden of Disease Study 2019”. **João Conde & GBD Consortium**. *The Lancet* (2021). Featured on COVER
23. “Facts and Figures on Materials Science and Nanotechnology Progress and Investment”. S. Talebian, T. Rodrigues, J. das Neves, B. Sarmiento, R. Langer, **João Conde\***. *ACS Nano* (2021). Featured on COVER
24. “Nanotechnology-based strategies to target and modulate the tumor microenvironment”. Barbara Mendes, João Coniot, Diana Sousa, **João Conde\***. *Trends in Cancer* (2021). Featured on COVER.
25. “Allosteric Antagonist Modulation of TRPV2 by Piperlongumine Impairs Glioblastoma Progression”. **João Conde**, R.A. Pumroy, C. Baker, T. Rodrigues, A. Guerreiro, B.B. Sousa, M.C. Marques, B.P. de Almeida, S. Lee, E.P. Leites, D. Picard, A. Samanta, S.H. Vaz, F. Sieglitz, M. Langini, M. Remke, R. Roque, T. Weiss, M. Weller, Y. Liu, S. Han, F. Corzana, V.A. Morais, C.C. Faria, T. Carvalho, P. Filippakopoulos, B. Snijder, N.L. Barbosa-Morais, V.Y. Moiseenkova-Bell, G.J.L. Bernardes. *ACS Central Science* (2021) Featured on COVER.
26. “CRISPR Systems for COVID-19 Diagnosis” H. Rahimi, M. Salehiabar, M. Barsbay, M. Ghaffarlou, T. Kavetsky, A. Sharafi, S. Davaran, Subhash C. Chauhan, H. Danafar, S. Kaboli, H. Nosrati, M.M. Yallapu, and **João Conde\***. *ACS Sensors* (2021) Featured on COVER.
27. “Ultrahigh penetration and retention of graphene quantum dot mesoporous silica nanohybrids for image guided tumor regression”. R. Prasad\*, N.K. Jain, A.S. Yadav, M. Jadhav, N.N.V. Radharani, M. Gorain, G.C. Kundu, **João Conde\***, R. Srivastava\*. *ACS Applied Bio Materials* (2021) Featured on COVER.
28. “Osteogenic Differentiation of Human Mesenchymal Stem Cells by the Single Action of Luminescent Polyurea Oxide Biodendrimers”. Rita F. Pires, **João Conde\*** and Vasco D.B. Bonifacio\*. *ACS Applied Bio Materials* (2020).
29. “Revisiting Gene Delivery to the Brain: Silencing and Editing” (2021 Biomaterials Science Emerging Investigators Issue). João Coniot, Sepehr Talebian, Susana Simões, Lino Ferreira\*, **João Conde\***. *Biomaterials Science* (2020) Featured on COVER.
30. “Stepwise Assembly of Multimode Liposomal Nanotheranostic Agent for Targeted In Vivo Bioimaging and NIR Light Mediated Cancer Therapy”. R. Prasad, N.K. Jain, A.S. Yadav, D.S. Chauhan, J. Devrukhkar, M.K. Kumawat, S. Shinde, M. Gorain, A.S. Thakor, G.C. Kundu, **João Conde\***, R. Srivastava\*. *Nature Communications Biology* (2020).
31. “Biomimetic cancer cell membrane coated-nanosystems as next-generation cancer therapies”. M. Pereira-Silva, A.C. Santos, **João Conde**, C. Hoskins, A. Concheiro, C. Alvarez-Lorenzo, F. Veiga. *Expert Opinion on Drug Delivery* (2020).



32. “Why Go NANO on COVID-19 pandemic?”. Sepehr Talebian and **João Conde\***. *Matter (Cell Press)* (2020).
33. “Nanotechnology-based disinfectants and sensors for SARS-CoV-2” S. Talebian, G.G. Wallace, A. Schroeder, F. Stellacci and **João Conde\***. *Nature Nanotechnology* (2020) COVID-19 Special Issue.
34. “Localized Nanotheranostics: Recent developments in Cancer Nanomedicine”. R. Prasad, N.K. Jain, **João Conde\***, R. Srivastava. *Materials Today Advances* (2020).
35. “Above and beyond Cancer Therapy: translating biomaterials into clinics” **João Conde\*** *Trends in Cancer* (2020).
36. “Tetrazine carbon nanotubes for pretargeted in vivo ‘click-to-release’ bioorthogonal imaging” H. Li, **João Conde**, A. Guerreiro, G.J.L. Bernardes. *Angewandte Chemie International Edition* (2020). VIP paper. Featured on COVER.
37. “Platinum-triggered Bond-cleavage of Pentynoyl amide and N-propargyl handles for Drug-Activation” B.L. Oliveira, B.J. Stenton, Unnikrishnan V.B., C.R. Almeida, **João Conde**, M. Negrão, F.S.S. Schneider, C. Cordeiro, M.G. Ferreira, G.F. Caramori, J.B Domingos, R. Fior and G.J.L. Bernardes. *Journal of the American Chemical Society* (2020). Featured on COVER.
38. “Prolonged Local In Vivo Delivery of Stimuli-Responsive Nanogels That Rapidly Release Doxorubicin in Triple-Negative Breast Cancer Cells”. Y. Zhang, P. Dosta, **João Conde**, N. Oliva, M. Wang and N. Artzi. *Advanced Healthcare Materials* (2020). Featured on COVER.
39. “Oral pH sensitive GNS@ab Nanoprobes for targeted therapy of Helicobacter Pylori without disturbance gut microbiome” X. Zhi, Y. Liu, L. Lin, M. Yang, L. Zhang, L. Zhang, Y. Liu, G. Alfranca, L. Ma, Q. Zhang, H. Fu, **João Conde**, X. Di, J. Ni, J. Song, D. Cui. *Nanomedicine: Nanotechnology, Biology and Medicine* (2019).
40. “Gastric parietal cell and Intestinal goblet cell secretion: a novel cell-mediated in vivo nanoparticle clearance pathway enhanced with diarrhea via Chinese Herbs”. Y. Liu, K. Liu, M. Yang, Y. Han, Q. Zhang, **João Conde**, Y. Yang, Y. Han, G. Alfranca, Y. Wang, J. Song, Y. Zhang, J. Ni, J.M. de la Fuente, D. Cui. *Nanoscale Research Letters* (2019).
41. “Biopolymers for anti-tumor implantable drug delivery systems: Recent advances and future outlook”. S. Talebian, S. Wadeb, J. Foroughi, K. L. Vineb, A. Dolatshahi-pirouz, M. Mehrali, **João Conde**, G. Wallace. *Advanced Materials* (2018).
42. “Ferritin nanocarrier traverses the blood brain barrier and kills glioma”. K. Fan, X. Jia, M. Zhou, **João Conde**, J. He, J. Tian, X. Yan. *ACS Nano* (2018).
43. “Nanoparticle-antagomiR based targeting of miR-31 to induce osterix and osteocalcin expression in mesenchymal stem cells”. M. McCully, **João Conde**, P.V. Baptista, M. Mullin, M.J. Dalby, C.C. Berry. *PLOS ONE* (2018).
44. “Plasmonic gold nanoparticles for detection of fungi and human cutaneous fungal infections” T. Sojinrin, **João Conde\***, K. Liu, J. Curtin, H.J. Byrne H, D. Cui, F. Tian\*. *Analytical and Bioanalytical Chemistry* (2017). Featured on COVER.
45. “Fullerene: Biomedical Engineers Get to Revisit an Old Friend” S. Goodarzi, T. Da Ros, **João Conde**, F. Sefat and M. Mozafari. *Materials Today* (2017).
46. “Designing Hydrogels for On-Demand Therapy” N. Oliva, **João Conde**, K. Wang and N. Artzi. *Accounts of Chemical Research* (2017).
47. Smart NIR linear and nonlinear optical nanomaterials for cancer theranostics: Prospects in photomedicine”. T.M. Liu, **João Conde\***, T. Lipiński, A. Bednarkiewicz and C-C. Huang. *Progress in Materials Science* (2017).

48. “Gold Nanostars for real-time intracellular and in vivo SERS detection combined with drug delivery via plasmonic-tunable Raman/FTIR imaging”. F. Tian, **João Conde\***, C. Bao, Y. Chen, J. Curtin and D. Cui. *Biomaterials* (2016).
49. “Revisiting the ‘one material fits all’ rule for cancer nanotherapy”. **João Conde\***, N. Oliva, N. Artzi\*. *Trends in Biotechnology* (2016).
50. “Biomaterials for Metastasis: Bridging the Gap between Basic and Translational Research” **João Conde**, N. Shomron and N. Artzi. *Advanced Healthcare Materials* (2016). VIP paper. Featured on COVER.
51. “Revisiting the classification of NIR absorbing/emitting Nanomaterials for in vivo bio-applications”. T-M. Liu, **João Conde\***, T. Lipinski, A. Bednarkiewicz, C-C. Huang. *Nature Asia Materials* (2016).
52. “3D hydrogel scaffold doped with 2D materials for biosensors and bioelectronics”. H.S. Song, O.S. Kwon, **João Conde\*** and N. Artzi. *Biosensors & Bioelectronics* (2016).
53. “Gold Nanoprisms as a hybrid in vivo Cancer Theranostic platform for in situ Photoacoustic Imaging, Angiography and localized Hyperthermia”. C. Bao, **João Conde**, F. Pan, C. Li, C. Zhang, F. Tian, S. Liang, J.M. de la Fuente and D. Cui. *Nano Research* (2016).
54. “Chiral Antioxidant-based Gold Nanoclusters Reprogram DNA Epigenetic Patterns”. Y. Ma, H. Fu, C. Zhang, S. Cheng, J. Gao, Z. Wang, W. Jin, **João Conde\*** and D. Cui. *Scientific Reports* (2016).
55. “Local triple-combination therapy results in tumour regression and prevents recurrence in a colon cancer model”. **João Conde\***, N. Oliva, Y. Zhang and N. Artzi. *Nature Materials* (2016). Highlighted in *Science Translational Medicine* and *Science Bulletin*.
56. “Local microRNA delivery targets Palladin and prevents metastatic breast cancer”. A. Gilam, **João Conde**, D. Weissglas-Volkov, N. Oliva, N. Artzi, N. Shomron. *Nature Communications* (2016).
57. “Self-assembled RNA-triple-helix hydrogel scaffold for microRNA modulation in the tumour microenvironment”. **João Conde\***, N. Oliva, M. Atilano, H.S. Song, N. Artzi. *Nature Materials* (2016). Highlighted in *Science Translational Medicine* and *The Scientist*.
58. “Dual-Color Emissive Upconversion Nanocapsules for Differential Cancer Bioimaging in vivo”. O.S. Kwon, H.S. Song, **João Conde**, H. Kim, N. Artzi and J.H. Kim. *ACS Nano* (2016).
59. “Implantable hydrogel embedded dark-gold nanoswitch as a theranostics probe to sense and overcome cancer multidrug resistance”. **João Conde\***, N. Oliva, N. Artzi. *PNAS* (2015). Highlighted in *Nature Reviews Drug Discovery*.
60. “Bioresponsive antisense DNA gold nanobeacons as a hybrid in vivo theranostics platform for the inhibition of cancer cells and metastasis”. C. Bao, **João Conde\***, J. Curtin, N. Artzi, F. Tian, D. Cui. *Scientific Reports* (2015).
61. “Personalizing biomaterials for precision nanomedicine in light of local tissue microenvironment”. N. Oliva, S. Unterman, Y. Zhang, **João Conde**, H.S. Song and N. Artzi. *Advanced Healthcare Materials* (2015). Featured on COVER.
62. “Dual targeted immunotherapy via in vivo delivery of bio-hybrid RNAi-peptide nanoparticles to tumour-associated macrophages and cancer cells”. **João Conde\***, C. Bao, Y. Tan, D. Cui, E.R. Edelman, H.S. Azevedo, H.J. Byrne, N. Artzi, F. Tian. *Advanced Functional Materials* (2015). VIP paper. Featured on COVER.
63. “RNAi nanomaterials targeting immune cells as an anti-tumor therapy: the missing link in cancer treatment?” **João Conde\***, C. Arnold, F. Tian and N. Artzi. *Materials Today* (2015)

64. “The next generation of smart gold nanobeacons: nanotheranostics is ready for prime-time”. **João Conde\*** and N. Artzi. *Nanomedicine (Lond.)* (2015).
65. “Are RNAi and miRNA therapeutics truly dead?”. **João Conde\***, N. Artzi. *Trends in Biotechnology* (2015).
66. “Target-Responsive DNA/RNA nanomaterials for microRNA sensing and inhibition: the jack-of-all-trades in cancer nanotheranostics?”. **João Conde\***, E.R. Edelman, N. Artzi. *Advanced Drug Delivery Reviews* (2015).
67. “15 years on siRNA delivery: beyond the State-of-the-Art on inorganic nanoparticles for RNAi therapeutics”. **João Conde\***, A. Ambrosone, Y. Hernandez, F. Tian, M. McCully, C.C. Berry, P.V. Baptista, C. Tortiglione, J.M. de la Fuente. *Nano Today* (2015).
68. “Editorial: Cancer Nanotheranostics - What have we learned so far?”. **João Conde\***, F. Tian, J.M. de la Fuente, P.V. Baptista. *Frontiers in Chemistry* (2015).
69. “The Golden Age in Cancer Nanobiotechnology: Quo vadis?”. **João Conde\***. *Frontiers in Bioengineering and Biotechnology* (2015).
70. “RNAi-based glyconanoparticles trigger apoptotic pathways for in vitro and in vivo enhanced cancer-cell killing”. **João Conde**, F. Tian, Y. Hernandez, C. Bao, P.V. Baptista, D. Cui, T. Stoöger and J.M. de la Fuente. *Nanoscale* (2015).
71. “Significance of the balance between intracellular glutathione and polyethylene glycol for successful release of small interfering RNA from gold nanoparticles” M. McCully, Y. Hernandez, **João Conde**, P.V. Baptista, J.M. de la Fuente, A. Hursthouse, D. Stirling and C.C. Berry. *Nano Research* (2015).
72. “Gold Nanoparticle-siRNA Mediated Oncogene Knockdown at RNA and Protein level, with associated Gene effects” H.W. Child, Y. Hernandez, **João Conde**, M. Mullin, P.V. Baptista, J.M. de la Fuente and C.C. Berry. *Nanomedicine (Lond.)* (2015).
73. “Investigating the role of shape on the biological impact of gold nanoparticles in vitro” F. Tian, M.J.D. Clift, A. Casey, P. del Pino, B. Pelaz, **João Conde**, H.J. Byrne, B. Rothen-Rutishauser, G. Estrada, J.M. de la Fuente and T. Stoeger. *Nanomedicine (Lond.)* (2015).
74. “POxylated polyurea dendrimers: Smart core-shell vectors with IC50 lowering capacity”. R.B. Restani, **João Conde**, R.F. Pires, P. Martins, A.R. Fernandes, P.V. Baptista, V.D.B. Bonifácio and A. Aguiar-Ricardo. *Macromolecular Bioscience* (2015).
75. “Polyurea dendrimer for efficient cytosolic siRNA delivery” R.B. Restani, **João Conde**, P.V. Baptista, M.T. Cidade, A.M. Bragança, J. Morgado, I.J. Correia, A. Aguiar-Ricardo and V.D.B. Bonifácio. *RSC Advances* (2014).
76. “A promising road with challenges: where gold nanoparticles are in translational research?” C. Bao, **João Conde**, E. Polo, P. del Pino, M. Moros, P.V. Baptista, V. Grazu, D. Cui and J.M. de la Fuente. *Nanomedicine (Lond.)* (2014).
77. “Antibody-Drug gold nanoantennas with Raman spectroscopic fingerprints for in vivo tumour theranostics.” **João Conde\***, C. Bao, D. Cui, P. Baptista, F. Tian. *Journal of Controlled Release* (2014).
78. “Revisiting 30 years of Biofunctionalization and Surface Chemistry of Inorganic Nanoparticles for Nanomedicine.” **João Conde\***, J.T Dias, V. Grazú, M. Moros, P.V. Baptista, Jesús M. de la Fuente. *Frontiers in Chemistry* (2014).
79. “A Gold-nanobeacon system for Gene therapy: evaluation of Genotoxicity, Cell toxicity and Proteome profiling analysis” **João Conde**, M. Larginho, A. Cordeiro, L.R. Raposo, P.M. Costa, S. Santos, M.S. Diniz, A.R. Fernandes and P.V. Baptista. *Nanotoxicology* (2014).

80. “In vivo tumour targeting via nanoparticle-mediated therapeutic siRNA coupled to inflammatory response in lung cancer mouse models.” **João Conde**, F. Tian, Y. Hernández, C. Bao, D. Cui, K.P. Janssene, M.R. Ibarra, P.V. Baptista, T. Stoöger and J.M. de la Fuente. *Biomaterials* (2013).
81. “Gold-Nanobeacons as a theranostic system for the detection and inhibition of specific genes”. **João Conde**, J. Rosa and P.V. Baptista. *Nature Protocol Exchange* (2013).
82. “Nanomaterials for reversion of multidrug resistance in cancer: a new hope for an old idea?” **João Conde\***, J.M. de la Fuente, P.V. Baptista. *Frontiers in Pharmacology* (2013).
83. “Gold-Nanobeacons for simultaneous gene specific silencing and intracellular tracking of the silencing events.” **João Conde**, J. Rosa, J.M. de la Fuente and P.V. Baptista. *Biomaterials* (2013).
84. “Design of Multifunctional Gold Nanoparticles for in vitro and in vivo Gene Silencing.” **João Conde**, A. Ambrosone, V. Sanz, Y. Hernández, V. Marchesano, F. Tian, H. Child, C.C. Berry, M.R. Ibarra, P.V. Baptista, C. Tortiglione and J.M. de la Fuente. *ACS Nano* (2012).
85. “Effect of PEG biofunctional spacers and TAT peptide on dsRNA loading on Gold Nanoparticles”. V. Sanz, **João Conde**, Y. Hernández, P.V. Baptista, M.R. Ibarra and J.M. de la Fuente. *Journal of Nanoparticle Research* (2012).
86. “Modification of Plasmid DNA Topology by Histone-Mimetic Gold Nanoparticles”. **João Conde**, P.V. Baptista, Y. Hernández, V. Sanz and J.M. de la Fuente. *Nanomedicine (Lond.)* (2012).
87. “Gold-Nanobeacons for Real-Time Monitoring of RNA Synthesis”. J. Rosa, **João Conde**, J.M. de la Fuente, J.C. Lima and P.V. Baptista. *Biosensors & Bioelectronics* (2012).
88. “Noble Metal Nanoparticles for Biosensing Applications” G. Doria, **João Conde**, B. Veigas, L. Giestas, C. Almeida, M. Assunção, J. Rosa and P.V. Baptista. *Sensors (Basel)* (2012).
89. “Noble Metal Nanoparticles Applications in Cancer” **João Conde**, G. Doria and P.V. Baptista. *Journal of Drug Delivery* (2012).
90. “Nanophotonics for Molecular Diagnostics and Therapy Applications” **João Conde**, J. Rosa, J.C. Lima and P.V. Baptista. *International Journal Photoenergy* (2012).
91. “Genotoxic effects of occupational exposure to lead and influence of polymorphisms in genes involved in lead toxicokinetics and in DNA repair”. J. García-Lestón, J. Roma-Torres, M. Vilares, R. Pinto, J. Prista, J.P. Teixeira, O. Mayan, **João Conde**, M. Pingarilho, J.F. Gaspar, E. Pásaro, J. Méndez and B. Laffon. *Environment International* (2012).
92. “Alloy Metal Nanoparticles for Multicolour Cancer Diagnostics”. P.V. Baptista, G. Doria and **João Conde**. *Proceedings of SPIE* (2011).
93. “In vitro Transcription and Translation Inhibition via DNA functionalized Gold Nanoparticles” **João Conde**, J.M. de la Fuente and P.V. Baptista. *Nanotechnology* (2010).
94. “Use of Cyclodextrins as Scavengers of Inhibitory Photo-products in Light controlled in vitro Synthesis of RNA”. A. Vidal Pinheiro, **João Conde**, A.J. Parola, J.C. Lima and P.V. Baptista. *Journal of Photochemistry and Photobiology A: Chemistry* (2010).
95. “RNA Quantification using Gold Nanoprobes - application to Cancer Diagnostics”. **João Conde**, J.M. de la Fuente and P.V. Baptista. *Journal of Nanobiotechnology* (2010).
96. “Association of common variants in Mismatch Repair Genes and Breast Cancer susceptibility: a Multigene study”. **João Conde**, S.N. Silva, A.P. Azevedo, V. Teixeira, J.E. Pina, J. Rueff and J.F. Gaspar. *BMC Cancer* (2009).

## BOOKS and BOOK CHAPTERS (\* corresponding author)

1. “Handbook of Nanomaterials for Cancer Theranostics” 1<sup>st</sup> Edition, *Editor: **João Conde***, Elsevier, 2018.
2. “Displaying biofunctionality on materials through templated self-assembly”, K. Shuturminska, C. O'Malley, D. W. P. Collis, **João Conde**, H. S. Azevedo, *in Self-Assembling Biomaterials: Molecular Design, Characterization and Application in Biology and Medicine, Elsevier, 2018.*
3. “Empowering the potential of cell-penetrating peptides for targeted intracellular delivery via molecular self-assembly”, Y. Shi, **João Conde**, H. S. Azevedo, *in Peptides and Peptide-based Biomaterials and their Biomedical Applications*, Eds. A. Sunna, A. Care, P. Bergquist, *Springer International Publishing AG, Cham.*
4. “Multifunctional Gold Nanocarriers for Cancer Theranostics – From bench to bedside and back again?” **João Conde\***, F. Tian, P.V. Baptista., J.M. de la Fuente. *in Nano-Oncologicals: New Targeting and Delivery Approaches (2014), Springer Science+Business Media. Controlled Release Society.*
5. “RNA Quantification Using Noble Metal Nanoprobes: Simultaneous Identification of Several Different mRNA Targets Using Colour Multiplexing and Application to Cancer Diagnostics.” **João Conde**, G. Doria, J.M. de la Fuente and P.V. Baptista\*. *in Nanoparticles in Biology and Medicine: Methods and Protocols Series (2012). Humana Press, Springer Protocols.*

## CONFERENCE & SEMINAR PRESENTATIONS

- Speaker at the Sustainable Value Creation Summit (SVCS) “How to Create Value using basic/fundamental science”, Nova SBE, May 2023, Portugal (*Invited*).
- Roundtable titled mRNA: The next revolution, Science|Business and Moderna, April 2023, Brussels, Belgium (*Invited*).
- Nanomedicine Seminar Series – “Working on the landscape of Precision Nanomedicine in Oncology” – Houston Methodist Research Institute, Houston Methodist Hospital, March 2023, Houston, USA (*Invited*).
- VIII Semana da Bioengenharia – Keynote Speaker – “It's nano or never: The importance of nanotechnologies in the healthcare future”, Instituto Superior Técnico (IST), March 2023, Portugal (*Invited*).
- ITQB PhD Program 2022 - MolBioS Doctoral Program: Nanoprocess for Life Science, March 2022, Portugal (*Invited*).
- “Application of multifunctional nano-and-biomaterials for cancer therapy and diagnosis” - Master Program in Biopharmaceutical Sciences, Oncobiology, FFUL, February 2022, Portugal (*Invited*).
- BioMedicine and BioSciences Seminar Series - University of Bergen (UiB), February 2022, Norway (*Invited*).
- “TIPS for applying to CEEC 5th edition 2022?” - Lyris, Advanced Science Education, January 2022 (*Invited*).
- Biotech in Action S2: Water Cooler Talk - Massachusetts Institute of Technology (MIT), Harvard–MIT Division for Health Sciences and Technology, July 2021, Boston, Massachusetts, USA (*Invited*).
- “The story behind my path in Cancer NanoMedicine” at the PostDoc ShowCase 2<sup>nd</sup> edition - Department of Pharmacy, University of Naples Federico II, June 2021, Italy (*Invited*).

- 9<sup>th</sup> Session IST- MedNetworking – To see or not to see: How Nanotechnology is redefining Medicine, Instituto Superior Técnico (IST), May 2021, Portugal (*Invited*).
- JorTec 2021 - Jornadas Tecnológicas (JorTec) da Faculdade de Ciências e Tecnologia, February 2021, Portugal (*Invited*).
- Keynote Speaker - 13<sup>o</sup> Encontro Nacional de Química Orgânica/6<sup>o</sup> Encontro Nacional de Química Terapêutica (13ENQO/6ENQT), January 2020, Portugal (*Invited*).
- Seminar, March 2017, University of Glasgow, Institute of Molecular Cell and Systems Biology, Glasgow, Scotland (*Invited*).
- Nanomedicine Seminars, February 2017, Trinity College Dublin, School of Medicine, Dublin, Ireland (*Invited*).
- 10<sup>th</sup> World Biomaterials Congress, May 2016, Montreal, Canada.
- 11<sup>th</sup> Annual Broad Retreat - Broad Institute of MIT and Harvard, December 2015, Boston, Massachusetts, USA.
- Society for Biomaterials 2015, April 2015, North Carolina, USA.
- 4<sup>th</sup> International Conference on Multifunctional, Hybrid and Nanomaterials, March 2015, Barcelona, Spain.
- 8<sup>th</sup> International Conference of Coelenterate Biology, December 2013, North Beach, Eilat, Israel.
- Collaborative Congress of the European Society for Gene and Cell Therapy and the Spanish Society for Gene and Cell Therapy, October 2013, Madrid, Spain.
- International Conference on Materials for Advanced Technologies 2013. Symposium R: Ecological and Health Impact of Nanomaterials and Nanotechnology, July 2013, Singapore.
- European Conference of Human Genetics 2013, June 2013, Paris, France.
- E-MRS 2013 SPRING MEETING, Bionanomaterials for imaging, sensing and actuating, May 2013, Strasbourg, France.
- Elsevier 3<sup>rd</sup> International Conference on Multifunctional, Hybrid and Nanomaterials (Hybrid Materials 2013), March 2013, Sorrento, Italy.
- Materials Research Society Fall Meeting, November 2012, Boston, Massachusetts, USA.
- NanoMed2012, International Conference on Nanotechnology in Medicine, November 2012, University College London, London, UK.
- American Chemical Society Spring 2012 National Meeting, March 2012, San Diego, California, USA.
- Miami 2012 Winter Symposium: Nanotechnology in Biomedicine, February 2012, Miami, USA.
- SPIE West 2012, San Francisco, USA.
- SPIE West 2011, Colloidal Quantum Dots/Nanocrystals for Biomedical Applications VI, February 2011, San Francisco, USA.
- TNT2010 – Trends in Nanotechnology, September 2010, Braga, Portugal.
- National Congress MicroBiotec'09, 2009, Vilamoura, Portugal.
- EURONANOFORUM 2009. Nanotechnology for Sustainable Economy. European and International Forum on Nanotechnology, June 2009, Prague, Czech Republic.
- XXXIV Genetic Journeys - Human Cancer Genetics and Genotoxicity, Portuguese Society of Human Genetics, 2009, Lisbon, Portugal.